Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, February 1, 2023
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
[ Wed, Feb 01st 2023
] - WOPRAI
Silvan Tuerkcan Maintained (TSHA) at Buy with Decreased Target to $4 on, Feb 1st, 2023
Silvan Tuerkcan of JMP Securities, Maintained "Taysha Gene Therapies, Inc." (TSHA) at Buy with Decreased Target from $6 to $4 on, Feb 1st, 2023.
Silvan has made no other calls on TSHA in the last 4 months.
There are 3 other peers that have a rating on TSHA. Out of the 3 peers that are also analyzing TSHA, 2 agree with Silvan's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Michael Ulz of "Morgan Stanley" Downgraded from Buy to Hold and Held Target at $3 on, Friday, January 27th, 2023
- Salveen Richter of "Goldman Sachs" Downgraded from Strong Buy to Hold and Decreased Target to $3 on, Wednesday, November 9th, 2022
This is the rating of the analyst that currently disagrees with Silvan
- Yanan Zhu of "Wells Fargo" Maintained at Buy with Decreased Target to $10 on, Wednesday, January 4th, 2023
